Cyprotex PLC Cyprotex PLC - Rule 2.9 Announcement (3708M)
13 Outubro 2016 - 3:00AM
UK Regulatory
TIDMCRX
RNS Number : 3708M
Cyprotex PLC
13 October 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Cyprotex PLC
("Cyprotex" or "the Company")
Rule 2.9 Announcement - Relevant Securities in Issue
In accordance with Rule 2.9 of the Takeover Code, Cyprotex PLC,
(AIM: CRX), confirms that it has the following securities in
issue:
-- 22,509,042 Ordinary Shares of 1 pence each in issue at the
close of business on 12 October 2016 and the Ordinary Shares in the
Company are admitted to trading on AIM under the UK ISIN code
GB00BP25RZ14; and
-- 4,584,645 of unsecured Convertible Loan Notes due in 30
September 2018 (the "Convertible Notes"). The Convertible Notes are
convertible into Ordinary Shares in Cyprotex at a price of 60 pence
per share. The Convertible Notes are admitted to the Official List
of the Cayman Islands Stock Exchange under the International
Securities Identification Number GB00BQ1XZQ04.
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad, Broker & Rule Tel: +44 (0)20 7496
3 Adviser to Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Brown Gibbons Lang & Company Tel: +1 312 658
(Financial Adviser to Cyprotex) 4774
John Riddle jriddle@bglco.com
J. Kyle Brown kbrown@bglco.com
Notes to Editors
About Cyprotex PLC
Cyprotex is quoted on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1500 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM) and
chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, please visit www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RTTGGGRUUUPQGGP
(END) Dow Jones Newswires
October 13, 2016 02:00 ET (06:00 GMT)
Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024